AG真人官方

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN or 鈥渆nGene鈥�), a clinical-stage, non-viral gene therapy company, today announced that management will participate in the following investor conferences in September:

2025 Wells Fargo Healthcare Conference
Date: Wednesday, September 3, 2025
Time: 8:45 a.m. ET

H.C. Wainwright 27^th Annual Global Investment Conference
Date: Monday, September 8, 2025
Time: 1:30 p.m. ET

Morgan Stanley 23^rd Annual Global Healthcare Conference
Date: Wednesday, September 10, 2025
Time: 1:50 p.m. ET

A live webcast of these events can be accessed under the 鈥淚nvestors鈥� section of the enGene website at and will be archived there for 90 days.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene鈥檚 lead program is detalimogene voraplasmid (also known as detalimogene, and previously EG-70) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a registrational cohort studying detalimogene in high-risk, Bacillus Calmette-Gu茅rin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene鈥檚 proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.

To learn more, please visit and follow us on , and .

View source version on businesswire.com:

For media contact:

[email protected]



For investor contact:

[email protected]

Source: enGene Holdings Inc.